Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.
Zhuoyuan YuHaifan XuMiao FengLiqun Chen
Published in: Cancer chemotherapy and pharmacology (2024)
We constructed a machine learning model for predicting grade ≥ 2 bevacizumab-induced proteinuria, which may provide proteinuria risk assessment for applying bevacizumab in patients with metastatic colorectal cancer.